LOI for joint venture with Rakovina Therapeutics — pairing their dual PARP/HDAC inhibitor kt-3283 with EnsaliX-designed patterned lipid nanoparticles to clear the delivery barrier standing between the molecule and the clinic.
TSX-V: RKV — a Vancouver-based oncology company using AI-powered drug discovery to design small molecules against validated cancer targets.
Co-development and co-ownership of the asset — shared IP, shared milestones, shared upside.
Advancing to in vitro & in vivo characterization following first formulation data at AACR 2026.
Rakovina's candidate kt-3283 — a single molecule that inhibits both PARP and HDAC — showed potent anti-tumor activity in vitro across models.
But weak bioavailability and metabolic instability stood between the molecule and the clinic. The mechanism was compelling; what it lacked was a way to get there intact.
Rakovina brings the molecule plus its in-house pharmacology, toxicology, and in vivo models; NanoPalm owns delivery, designing a patterned-LNP formulation of kt-3283 on the EnsaliX platform. Shared IP, shared milestones, shared upside.
kt-3283 plus in-house pharmacology, toxicology, and in vivo tumor models.
A patterned-LNP formulation of kt-3283 designed on the EnsaliX platform.
Co-development and co-ownership, anchored in a letter of intent signed August 2025.
AI-designed patterned lipid nanoparticle tailored to carry kt-3283.
The small molecule is formulated into the designed pLNP system.
Tested in Rakovina's pharmacology and tumor models.
Both sides review the same data at each gate.
First preclinical formulation data presented — Poster #6373, Drug Delivery session.
Current stage — advancing to in vitro & in vivo characterization.
Co-development & co-ownership of the asset.
At AACR 2026, the program presented its first preclinical formulation data for pLNP/kt-3283. The EnsaliX-designed nanoparticles came together cleanly — consistent particle size, stable in suspension, and a textured surface expected to help cells take them up — clearing the way to biological testing.
Next: confirming PARP and HDAC activity, ADME, and efficacy in tumor models.
If a promising molecule is held back by delivery, let's build the formulation together — shared IP, shared milestones, shared upside.